A recent paper in the November 2010 issue of Childhood Obesity (see link) further confirms the association between the occurrence of childhood obesity and an increased adult risk of cardiovascular and metabolic disorders. Â These include hypertension, elevated cholesterol and insulin resistance.
With high profile setbacks for obesity drugs (lorcaserin, sibutramine, Qnexa), including withdrawals and regulatory denials, the thrust of obesity intervention will continue to be in bariatric surgical or other device interventions, giving support to investment in a number of medtech companies. Â Setting aside that the Childhood Obesity paper further reinforces the premise that the best option to address obesity remains preventing its occurrence, the drive in most well developed economies, which stubbornly demonstrate a continued rise in the prevalence of obesity and all its sequellae, surgery and device interventions have gained a prominence in clinical practice that is unlikely to fade for several years.
Over 30 companies are intensely active in marketing and developing device technologies or developing obesity drugs (the only approved drug is orlistat, Xenical, and it has a tenuous “monopoly” on obesity drugs). Even the possibility of Orexigen’s Contrave receiving approval (slated for panel review in December) is unlikely to stem the immediacy in demand for treatment options for the severely overweight.
Obesity products and technologies are the subject of a pending report (#S835) from MedMarket Diligence, LLC.